Detection of prostate cancer by prostate-specific antigen

Biomedicine and Pharmacotherapy

Volumn 55, Issue 3, 2001, Pages 130-134

  Egawa, S ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cancer mortality; Early detection; Prostate cancer; Quality of life; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CLINICAL PRACTICE; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; HUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; RISK BENEFIT ANALYSIS;

ADULT; AGED; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 0035054895     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0753-3322(01)00037-3     Document Type: Article

References (49)

1. Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing
2. Prostate carcinoma incidence and patient mortality. The effects of screening and early detection
3. Figures on cancer in Japan-1995
4. Prospective evaluation plan for randomised trials of prostate cancer screening
5. Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial of the National Cancer Institute
6. Evaluation of the digital rectal examination as a screening test for prostate cancer
7. Screening and early detection of prostate cancer
8. Normal levels of prostate-specific antigen (PSA)
9. A PSA threshold of 4.0 ng/mL for early detection of prostate cancer: The only rational approach for men 50 years old and older
10. The American Cancer Society national prostate cancer detection project: Findings on the detection of early prostate cancer in 2,425 men
11. Serum prostate specific antigen as prescreening test for prostate cancer
12. Detection of organ-confined prostate cancer is increased through prostate-specific antigen based screening
13. Screening for prostate carcinoma with prostate specific antigen
14. The nature of prostate cancer detected through prostate specific antigen based screening
15. European randomized study of screening for prostate cancer - The Rotterdam pilot study
16. Screening in general practice
17. Screening for prostate cancer
18. Screening for prostate cancer using serum prostate-specific antigen: A randomised, population-based pilot study in Finland
19. Early detection of prostate cancer. Results of a prostate specific antigen-based detection program in Japan
20. Mass screening for prostate carcinoma: A study in Hokkaido, Japan
21. Correlation of prostate-specific antigen before prostate cancer detection and clinicopathologic features: Evaluation of mass screening populations
22. Clinical evidence for and implications of the multistep development of prostate cancer
23. Incidence and etiology of prostate cancer
24. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer; results of a multicenter clinical trial of 6,630 men
25. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer
26. Prostate carcinoma incidence and patient mortality. The effects of screening and early detection
27. Questioning the value of screening for prostate cancer in asymptomatic men
28. Screening for prostate cancer: A decision analytic view
29. A decision analysis of alternative treatment strategies for clinically localized prostate cancer
30. Person-years of life lost due to cancer in the United States, 1970 and 1984
31. A critique of the decision analysis for clinically localized prostate cancer
32. Results of conservative management of clinically localized prostate cancer
33. Risk of progression and dying of clinically localized prostate cancer in Japan
34. Impact of life expectancy and tumor doubling time on the clinical significance of prostate cancer in Japan
35. Defining and updating the ACS guidelines for the cancer related check-up: Prostate and endometrial cancer
36. Periodic health examination, 1991 update
37. Screening for prostate cancer
38. Systematic sextant biopsies in 651 patients referred for prostate evaluation
39. Results of transrectal ultrasound-guided biopsies and clinical significance of Japanese prostate cancer
40. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen
41. Prostate specific antigen adjusted for the transition zone volume as an indicator of prostate cancer
42. PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL
43. The use of percent free PSA for early detection of prostate cancer
44. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease. A prospective multicenter clinical trial
45. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease
46. Serum prostate-specific antigen in a community-based population of healthy men: Establishment of age-specific reference ranges
47. Age- and race-specific reference ranges for prostate-specific antigen from a large community-based study